Although glial cell-line derived neurotrophic factor (GDNF) acts as a potent survival factor for dopaminergic neurons, it is not known if GDNF can directly alter dopamine synthesis.
survival factor for dopamine neurons and is necessary for differentiation and maintenance of this phenotype. GDNF administration protects dopaminergic neurons from neurotoxin-and axotomyinduced death. These beneficial effects of GDNF have led to the suggestion that this trophic factor could be used as a therapeutic agent for the treatment of Parkinson's disease (1) .
In addition to preventing the death of dopaminergic neurons, several studies have reported that GDNF can enhance dopamine levels and increase the quantal size of small synaptic vesicles in dopaminergic neurons (2, 3) . One possible mechanism for the increases in dopamine levels and quantal size is stimulation of tyrosine hydroxylase [EC 1.14.16.2; tyrosine 3-monooxygenase; L-tyrosine tetrahydropteridine: oxidoreductase (3-hydroxylating); TH] activity.
TH is the rate-limiting enzyme in the biosynthesis of dopamine, and therefore, the activity of this enzyme is likely to be a key determinant of dopamine levels. Although there have been reports of higher TH levels and more TH positive neurons in physically or chemically lesioned animals treated with GDNF, others indicate that GDNF cannot reverse injury-induced decreases in TH levels (4, 5, 6) . These apparently contradictory results are likely to be caused by two factors: 1) difficulty in distinguish the effect of GDNF as a survival factor from its ability to modulate dopamine synthesis in these in vivo studies; and 2) TH protein levels may not directly reflect its activity and dopamine biosynthesis.
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While enhanced transcription and translation can increase TH protein levels, the enzymatic activity is regulated by phosphorylation of the protein (7) . Phosphorylation of seryl residues (Ser19, Ser31 and Ser40) has been observed both in vitro and in situ, and protein kinases that phosphorylate each of these sites have been identified in part (8) . These studies report that phosphorylation at Ser31 and Ser40 correlates with stimulation of dopamine synthesis (9) . However, the effect of GDNF on phosphorylation of TH and its enzymatic activity has not been examined. The present study uses a TH expressing human neuroblastoma cell line and rat primary mesencephalic neuronal cultures in order to examine the effect of GDNF on TH phosphorylation. TH enzymatic activity and dopamine synthesis were measured to examine if GDNF-mediated alterations in TH phosphorylation are accompanied by changes in enzymatic activity and dopamine synthesis.
Experimental procedures:

Materials. A BE(2)-C human neuroblastoma cell line was obtained from American Type
Culture Collection (ATCC, Manassas, VA). Human recombinant GDNF and rat recombinant GDNF were purchased from R&D systems (Minneapolis, MN). Anti-synaptophysin polyclonal antibody and Alexa dye-conjugated secondary antibody were purchased from DakoCytomation (Carpinteria, CA) and Molecular Probes (Eugene, OR), respectively. Pan-specific anti-TH polyclonal antibody, phospho-specific antibody for rat TH (Ser31 and Ser40), and Anti-NeuN monoclonal antibody were from Chemicon (Temecula, CA). Anti-phospho-Erk1/2 polyclonal antibody and LY294002 were from Cell Signaling Technology (Beverly, MA). Okadaic acid and PD098059 were from Calbiochem (San Diego, CA). followed by incubation in serum-deprived culture medium including the inhibitor in the presence or absence of GDNF for 60 min. Cells were lysed and extracts were prepared as described above.
Prior to use, the cell lysate was sonicated and the amount of protein in each sample was measured by a Bradford assay using BSA as the standard.
Primary mesencephalic neuronal culture. Primary neurons were cultured from E15 SpragueDawley rat embryos. The ventral mesencephalic tissue was dissected out in an ice-cold DMEM/F12 culture medium followed by treatment with PBS (phosphate buffered-saline pH 7.4) containing 0.05 % trypsin and 0.53 mM EDTA (Gibco BRL) at 37 o C for 15 min. The treatment was terminated by adding an equal volume of the culture medium supplemented with 10 % fetal bovine serum. The tissue was resuspended in the culture medium and triturated using a 1 mL pipette tip 10 times followed by incubation on ice for 10 min. Suspended cells were removed and clumped materials at the bottom of the tube were again triturated using a 200 µL pipette tip sequentially purified first using phosphopeptide affinity columns, followed by removal of any residual non-phosphorylation-specific antibodies using non-phospho-peptide columns. Nonphosphorylated-specific antibodies for Ser31 and Ser40 were produced by immunizing rabbits with the appropriate peptides, and then purified using the nonphosphopeptide affinity chromatography followed by adsorption against a phosphopeptide column to remove crossreacting antibodies. The affinity-purified antibodies were characterized by western blotting.
Samples were resolved in a SDS-PAGE and transferred to an Immobilon-P (Millipore, Bedford, MA) membrane using a semi-dry transfer apparatus (Millipore). Membranes were blocked overnight in TBST (10 mM Tris pH 7.5, 150 mM NaCl, 0.05 % Tween-20) plus 5% BSA, and incubated with a primary antibody (1: 1,000 -2,500 dilution for phospho-and non-phospho-TH antibodies, 1:50,000 for pan-specific TH antibody, or 1:2,000 for phospho-Erk1/2 antibody) for 3 hr at room temperature. The migration of TH was confirmed using a pan-specific polyclonal antibody, which recognized both the phosphorylated and unphosphorylated forms of TH (Chemicon). In addition, commercially available phosphorylation-specific antibodies for Ser31 or Ser40 (Chemicon), which recognize rat TH were also used to corroborate immunoreactivity in rat neuronal culture. Following incubation with the primary antibody, membranes were washed 
Calculation of fractions of phosphorylated and non-phosphorylated TH.
The fractions of phosphorylated and non-phosphorylated TH at a single site can be calculated using the fold changes for phospho and non-phospho TH immunoreactivities. This can be achieved provided: 1) the total amount of TH remains constant over time and
2) increase/decrease in immunoreactivity is linearly related to the amount of corresponding antigen on the western blot. Let P 0 and Pt represent the fraction of phosphorylated TH at time zero, and at a later time t, respectively. N 0 and Nt represent the fractions of nonphosphorylated TH at time zero and at time t, respectively. Statistical analysis. Statistical significance was determined by a repeated-measures analysis of variance (ANOVA) followed by post-hoc analysis. Data were considered significant at P<0.05.
Statistical analysis was performed using either the integrated optical densities (western blot) or scintillation counts (enzyme activity assay).
Results:
Retinoic acid (RA) treatment induces neuronal morphology and increases the expression of synaptophysin and TH in BE(2)-C human neuroblastoma cells.
RA exposure has been shown to cause differentiation of BE(2)-C cells (10), (13) , resulting in dopamine-like neurons. BE(2)-C cells were treated with 10 µM all trans-retinoic acid, and morphological changes were examined using phase-contrast microscopy as well as by Kobori, N. Page 12 -12 -immunohistochemical staining for TH and synaptophysin, a synaptic-vesicle protein (Fig. 1a) .
Cells not exposed to RA possess short neurites and show weak synaptophysin and TH immunoreactivity (Fig 1a) . Differentiation by RA is associated with cessation of proliferation and extensive branching of the neuronal processes. By 6 days post-RA exposure, the expression of synaptophysin and TH are markedly increased (Fig 1a) . We next examined if this increase in TH immunoreactivity is accompanied by enhanced TH activity and dopamine synthesis. TH activity using cell extracts and dopamine synthesis in intact cells were measured as described in the Material and Methods section. Figure 1b shows that RA treatment significantly increases TH activity as compared to the untreated cells. In contrast, measurement of dopamine synthesis by monitoring 14 CO 2 production did not show any detectable synthesis in either untreated or RAtreated cells (data not shown). This could be due to the absence of L-aromatic amino acid decarboxylase activity, which catalyzes the conversion of L-DOPA to dopamine in these cells. It has been reported that other neuroblastoma cell lines also lack this enzyme and do not synthesize dopamine (14) . Dopamine inhibits its synthesis by directly binding to TH and this binding of dopamine is blocked when TH is phosphorylated on Ser40. Thus a lack of dopamine synthesis in BE(2)-C cells minimizes the involvement of Ser40 phosphorylation in regulating TH activity.
These cells are therefore useful in isolating the contribution of Ser31 phosphorylation to TH axtivity.
Characterization of TH antibodies.
Phosphorylation-and non-phosphorylation-specific antibodies were generated to examine phosphorylation changes in response to treatments. The specificity of the phospho-specific antibodies were evaluated using bacterially expressed bovine TH and by western blot analysis.
Kobori, N. Page 13 -13 -Bacterially expressed proteins are not phosphorylated as bacteria lack protein kinases required to phosphorylate TH (15) . Figure 1c shows that the pan-specific TH antibody detects bacterially expressed TH. As anticipated, the phosphorylation-specific antibodies for Ser40 or Ser31 did not detect bacterially expressed TH. In contrast, the non-phosphorylation-specific antibodies for Ser40 and Ser31 reacted with the TH protein. When BE(2)-C cell extracts were used, both phospho-specific antibodies detected a band slightly larger than the band detected in bovine adrenal gland protein extracts (Fig. 1d ). This observation is consistent with the reported size difference between human and bovine TH (16, 17) . The identity of this band was confirmed by reprobing the membranes with a pan-specific TH antibody (Fig. 1d, right) . Neither the panspecific, nor the phospho-specific, antibodies cross reacted with extracts from Jurkat T-cells, which do not express TH. Furthermore, preincubation of each of the phospho-specific antibodies with 20-fold molar excess of the phospho-peptide used for immunization blocked the corresponding immunoreactivity (Fig. 1d, lane 4) . The linear range for TH immunoreactivity in western blots was determined for all antibodies using increasing amounts of protein samples.
The immunoreactivity was found to increase in a linear manner with amounts of total protein ranging from 5 µg to 62 µg (data not shown). Subsequent experiments were performed using 10 to 30 µg total proteins.
GDNF treatment does not alter TH levels.
Although previous studies have shown that GDNF is a survival factor for dopamine neurons (4), (18), it is not clear if GDNF alters TH protein levels. GDNF binds to two receptors (GFRα1 and GFRα2) that recruit the Ret tyrosine kinase to the lipid raft (19) . This results in the phosphorylation of Ret at multiple tyrosine residues that serve as docking sites for intracellular 
GDNF treatment increases Ser31 and Ser40 phosphorylation.
The protein samples used to examine pan-TH immunoreactivity in Figure 2a were analyzed for changes in TH phosphorylation. Figure 2b shows representative western blots and summary data indicating that serum deprivation did not alter phospho-Ser40 immunoreactivity at any of the time points examined. In contrast, GDNF treatment significantly increased the phosphorylation of Ser40 as early as 30 min compared to both the serum deprived group ( * ) and the zero time point samples (+) used as controls. This increase in phospho-Ser40 immunoreactivity was detected for up to 3 hr post-GDNF application (Fig. 2b) . Changes in Ser40 phosphorylation were further examined by re-probing the membranes with Ser40 nonphosphorylation-specific antibodies. The immunoreactivity of non-phospho-Ser40 did not Kobori, N. Page 15 -15 -change as a result of serum deprivation, but was significantly decreased as a result of GDNF treatment for up to 60 min (Fig. 2c) . Consistent with the observed increases in immunoreactivity using the phospho-Ser40 antibody, the immunoreactivity using the non-phospho-Ser40 shows a corresponding decrease at the time points examined. (Fig. 2e) .
Erk activity is required for Ser31, but not Ser40, phosphorylation.
Previous studies have shown that phosphorylation of TH on Ser31 enhances enzymatic activity by increasing the Vmax of the enzyme. In contrast, phosphorylation of Ser40 increases TH activity by increasing the rate of dissociation of inhibitory catecholamines from the enzyme (12), (22) . Furthermore, in the absence of catecholamines, Ser40 phosphorylation does not increase TH activity (23) . It has been reported that Erk can phosphorylate Ser31 (12), (22) .
Therefore, we examined if the increases in Ser31 phosphorylation are due to GDNF-mediated To examine if Ser31 and Erk phosphorylation co-vary at different concentrations of GDNF, a dose-response study was carried out. Phospho-Ser31 and phospho-Erk immunoreactivities showed parallel increases (subtracting changes caused by serum deprivation) in a dosedependent manner up to 100 ng/mL GDNF (Fig. 3b) .
To evaluate if a causal link exists between Erk activity and Ser31 phosphorylation, the MEK inhibitors U0126 and PD098059 were used. Figure 3c shows that both U0126 and PD098059 blocked the serum-deprived and GDNF-induced increases in phospho-Erk immunoreactivity. This was accompanied by a corresponding decrease in phospho-Ser31 immunoreactivity (Fig. 3c) . Re-probing of these membranes with the pan-specific TH antibody indicated that the decrease in phospho-Ser31 immunoreactivity was not due to an overall change in the protein levels. To determine if PD098059 decrease Ser40 phosphorylation, membranes were re-probed with antibodies for phospho-Ser40. PD098059 did not alter the immunoreactivity of phospho-Ser40 (Fig 3c) . In addition to stimulation of the Erk cascade, the binding of GDNF to its receptors activates phosphoinositides-3,4,5 (PI3)-kinase (24, 25, 26, 27) .
To examine if the PI3-kinase cascade contributes to Ser31 phosphorylation, LY294002 was utilized. Figure 3d shows that LY294002 did not alter phospho-Erk or phospho-Ser31 immunoreactivities in either serum-deprived or GDNF-treated cells.
GDNF treatment increases TH activity.
To examine if GDNF-induced changes in TH phosphorylation in BE(2)-C cells results in altered enzymatic activity, in vitro assays were performed using cell lysates. (Fig. 4a) . Twenty micrograms of total protein was used in the subsequent experiments. Serum deprivation modestly increased TH activity at the 60 min time point (Fig. 4b) . Consistent with the effect of GDNF on Ser31 phosphorylation, TH activity was significantly augmented at the 60 min time point compared to the serumdeprived control. To examine if the inhibition of Ser31 phosphorylation by the MEK inhibitor blocks this increase in TH activity, cells were treated with GDNF for 30 min in the presence or absence of 5 µM U0126. GDNF-mediated increases in TH activity was completely blocked in the presence of U0126 (Fig. 4c) .
Fractional change of phospho-and non-phospho-TH following GDNF treatment.
Our western blot data indicated that the total amount of TH did not alter as a result of either serum deprivation or GDNF treatment, and the changes in phosphorylation detected using both the phospho-and non-phospho-specific antibodies were within the linear range. These conditions satisfy the assumptions made to derive to equations 5 and 6 and allow to calculate the fractions of phosphorylated and non-phosphorylated TH molecules (see Materials and Methods section). Since the maximal change in TH activity in response to GDNF treatment was detected at the 60 min time points, the calculations were performed using the fold changes observed at this time point. As shown in Table 1 , prior to serum deprivation approximately 15% of TH molecules were phosphorylated on Ser31. Serum deprivation increased the fraction of phosphorylated TH molecules to 30%, whereas GDNF treatment resulted in 56% of all TH molecules being phosphorylated on Ser31 (Table 1) .
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GDNF increases TH phosphorylation, but not TH protein levels, in primary dopaminergic cells.
Since BE(2)-C cells do not synthesize dopamine, we used primary rat mesencephalic cell cultures to examine if the increased phosphorylation of TH in response to GDNF exposure leads to enhanced dopamine synthesis. To characterize the cell population, double immunostainings using a neuron-specific marker, NeuN and pan-TH antibodies were performed. Figure 6a shows that approximately 95% of the cells in these cultures were NeuN-positive, and that 2.43 +/-0.25 percent (mean +/-SE) of neurons are TH positive in these primary cultures. These cell cultures were exposed to GDNF and cell extracts were prepared at different time points. The extracts were analyzed by western blotting using the pan-specific TH antibody. A representative western blot and the summary data compiled from five independent experiments in Figure 5b shows that GDNF treatment did not change TH immunoreactivity at any of the time points examined.
The protein samples used to examine pan-specific TH immunoreactivity in Figure 5b were further analyzed for TH phosphorylation. As shown in Figure 3 , the increases in Ser31 phosphorylation are due to GDNFmediated Erk activation in BE (2) (Fig. 6a, left and center) . Re-probing of the membrane with the phospho-Ser40 antibody followed by the pan-specific TH antibody indicated that U0126 did not affect Ser40 phosphorylation or TH protein levels (Fig. 6a, right) . As previous studies have shown that protein kinase A (PKA) can phosphorylate Ser40, we examined if GDNF-mediated Ser40 phosphorylation is altered by a PKA inhibitor, Rp-cAMPS. PhosphoSer40 immunoreactivity was significantly decreased by 50 µM Rp-cAMPS (Fig. 6b, left) . The membranes used for the western blotting of phospho-Ser40 were reprobed for phospho-Ser31, showing that phospho-Ser31 level was not affected by Rp-cAMPS (Fig. 6b, right) .
GDNF increases dopamine synthesis in primary neuronal cells.
Dopamine synthesis in mesencephalic neurons was measured using the CO 2 assay. Rp-cAMPS for an hour followed by the treatment with 50 ng/mL GDNF for 30 min, and CO2 assay was performed. Figure 7b shows that GDNF increases dopamine synthesis by approximately 3-fold. Rp-cAMPS treatment modestly decreased this GDNF-mediated enhanced dopamine synthesis. In contrast, U0126 significantly inhibited dopamine synthesis at two different concentrations. However, the degree of inhibition observed was similar at these two concentrations. Interestingly, treatment of cells with both U0126 and Rp-cAMPS completely blocked GDNF-stimulated dopamine synthesis.
Discussion:
The study of the effect of GDNF on dopaminergic cells has been primarily restricted to the investigation of its ability to maintain the survival of these neurons, and the usefulness of this factor as a potential therapy for diseases of the CNS (28). However, in addition to effects directly attributable to the survival of dopaminergic cells, results that appear to be related to altered dopamine biosynthesis (e.g. increases in quantal size) have been reported (2) . It has been hypothesized that increases in the level of TH, the rate-limiting enzyme in the synthesis of dopamine, may underlie these effects, although experiments investigating the levels of TH following GDNF exposure have yielded contradicting results (6) . As TH activity is modulated by changes in its phosphorylation state (7), we investigated the effect of GDNF on the phosphorylation of two key seryl residues. In this report, we have examined the effect of GDNF on TH phosphorylation and activity using a human neuroblastoma cell line and rat primary mesencephalic neuronal cultures. Exposure of these cells to GDNF increased TH activity, and in (12), (22) .
In this report, we present data to show that exposure of BE(2)-C cells to GDNF caused a rapid increase in Erk phosphorylation that lasted for up to 3hr. The phosphorylation of both Erk and Ser31 was significantly reduced by pretreatment with two different MEK inhibitors, suggesting that GDNF-induced Erk activity results in enhanced Ser31 phosphorylation leading to increased TH activity. The results presented in Table 1 show that serum deprivation increases the fraction of TH molecules, which are phosphorylated on Ser31 from 15% to 30%. This increase is accompanied by a 26% increase in TH activity. GDNF treatment increased the fraction of Ser31 phosphorylated TH molecules from 15% to 56%, a change accompanied by a 56% change in TH activity.
As observed using BE(2)-C cells, GDNF increased Ser31 phosphorylation in primary neuron cultures with comparable temporal changes (Fig 5d) . GDNF treatment also increased Erk phosphorylation in these cells. The increased phosphorylation of both Erk and Ser31 was GDNF-mediated enhanced dopamine synthesis was observed, returning the activity to the basal levels. In addition to a direct activation of TH via increased phosphorylation, GDNF can indirectly increase TH activity. For example, it has been reported that GDNF increases GTPcyclohydrolase I activity (a key enzyme in BH4 synthesis) and BH4 levels in primary dopamine neurons (34) . GTP-cyclohydrolase I activation was observed at the 24 hr and 48 hr, but not at 6 hr, following GDNF treatment. This suggest that increases in GTP-cyclohydrolase I and BH4 levels can contribute to TH activity at longer time points, and may not have contributed to the changes in TH activity observed in the present study.
Can chronic GDNF administration elevate dopamine levels? It has been reported that chronic GDNF treatment decreases TH protein level (6) . In our findings, TH activity is initially increased followed by a steady decline over time. The mechanism(s) for this decline in activity over time in the continued presence of GDNF is not known at present. Several mechanisms are plausible including receptor desensitization and activation of a protein phosphatase. Our Kobori, N. Page 24
-24 -preliminary examination shows that chronic treatment with GDNF causes a decrease in Ser19 phosphorylation (data not shown) consistent with a phosphatase activation. In addition to the effect of GDNF on TH phosphorylation and dopamine synthesis, it also acts as a potent survival factor and causes collateral sprouting of dopamine cells. Even if chronic GDNF treatments may not increase TH activity, its effect on dopamine cell survival and collateral sprouting may result in an overall increase in dopamine levels. This, however, remains to be demonstrated in animal models.
In conclusion, the present study shows that in addition to its survival effects, GDNF can increase the activity of the rate-limiting enzyme of dopamine biosynthesis, and suggests that impaired dopaminergic function can be acutely altered by GDNF treatment. Future studies will examine if administration of GDNF can alter the phosphorylation and activity of TH in vivo, and offer beneficial effects for neurological dysfunctions associated with decreased dopamine levels. RA treatment for 6 days (n=3) increased TH activity as assessed using the water assay. *, P < 0.05. 
Figure 4
Measurements of TH enzymatic activity in BE(2)-C cells using the water assay. a.
Radioactive water production increases in a linear fashion with respect to protein amount in the assay mixture (n=2). b. TH activity increases with GDNF treatment (n = 3). TH activity was plotted as fold-changes compared with the zero time point controls. *, P < 0.05 between GDNFtreated and -untreated groups. +, P < 0.05 compared with the zero time point controls. c. -31 -phospho-Ser40, but not phospho-Ser31, immunoreactivity. *, P < 0.05 between inhibitor-treated and -untreated groups. +, P < 0.05 between GDNF-treated and -untreated groups.
Figure 7
Measurement of dopamine synthesis in mesencephalic cell cultures using the CO 2 assay.
Results are plotted as the mean +/-SE. a. Dopamine synthesis, as measured by radioactive CO 2 production, is enhanced with increasing concentrations of GDNF. Cells were treated with GDNF for 30 min (n=3 per concentration). b. Inhibition of Erk activity by UO126 significantly reduced the GDNF-mediated increase in dopamine synthesis. The combination of Rp-cAMPS and U0126 blocked the GDNF effect on dopamine synthesis, resulting in CO 2 production comparable to untreated controls (n=3). *, P < 0.05 between inhibitor-treated and -untreated groups. +, P < 0.05 between GDNF-treated and -untreated groups.
